iCare HOME2 is described as an innovative self-tonometer, offering comprehensive insights into IOP fluctuations and peaks, as well as adding significant value to treatment decisions and assessments.
The device, available to patients now at Glaucoma Australia, enables clinicians to optimise care, monitor treatment efficacy and customise individual management for their patients, with all data accessible via cloud software.
“The difference between readings we obtain in the office and the data from the iCare HOME is like the difference between a single snapshot and a continuous movie of a patient’s daily life,” remarked renowned Canadian glaucoma specialist Dr Ike K. Ahmed.
For patients, iCare HOME2 is said to provide peace of mind and may help improve adherence to medication. It is described as easy-to-use, with the same gentle and accurate rebound technology as other iCare tonometers, and no anaesthesia or eye drops required.
